Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
bristol-myers squibb
5
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
5
×
biotech
celgene
clinical trials
johnson & johnson
pfizer
abbvie
aducanumab
biogen
deals
eli lilly
genentech
nonalcoholic steatohepatitis
affordable care act
What
bio
5
×
news
5
×
roundup
drug
nash
approved
biogen
biogen’s
companies
fda
week
adu
aducanumab
alzheimer’s
amyloid
angst
approval
august
bagged
beats
bids
billions
biopharmaceutical
biotech
brammer
busy
complicated
convo
days
decisions
depression
devices
digital
dire
disease
drugs
earlier
effects
epidemic
failure
Language
unset
Current search:
news
×
" bristol-myers squibb "
×
" wisconsin top stories "
×
bio
×
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Amyloid Angst, NASH News, Brammer Bagged & More
@xconomy.com
5 years ago
Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More